Something interesting is happening in the hedge fund world, and it's not another AI infrastructure bet. Managers are quietly rebuilding their defensive playbook, and the clearest sign is a broad rotation into heavyweight healthcare names. Think big pharma, managed care, and the kind of stocks that generate cash whether the economy is booming or sputtering.
For most of 2025, hedge funds have been all-in on mega-cap tech and AI infrastructure. But stretched valuations and rising rate volatility have a way of making even the most confident growth investors nervous. The solution? Add some ballast to the portfolio. According to data from 13F filings aggregated by HedgeFollow, healthcare emerged as the preferred defensive offset in Q3.
Why healthcare? It checks all the boxes smart money looks for when things get choppy: recession-resistant cash flows, blockbuster drug pipelines, and steady insurance revenue that doesn't disappear when the market gets weird.
The Big Names Getting Attention
Among the stocks drawing institutional capital, Eli Lilly And Co (LLY) and UnitedHealth Group Inc (UNH) are leading the charge.
Lilly's obesity and diabetes drug franchise continues to print money. Surging demand for incretin-based therapies is driving exceptional earnings momentum, and several funds added to their LLY exposure in Q3. It's the rare stock that works both as a mega-cap resilience play and a secular growth story. When you can get defensive stability and a compelling growth narrative in one ticker, that tends to attract attention.
UnitedHealth, meanwhile, offers exactly the kind of predictable revenue hedge funds crave during volatile periods. Q3 numbers showed strong premium growth and stable margins—a combination that makes UNH the textbook "risk-off but not bearish" pick. You're not betting on a recession, you're just acknowledging that predictable earnings look pretty good right now.
Other names seeing significant accumulation include Johnson & Johnson (JNJ), Elevance Health Inc (ELV), and Thermo Fisher Scientific Inc (TMO). The common thread? Scale, intellectual property depth, and durable cash generation. These aren't speculative bets—they're the stocks you buy when you want to stay invested but don't want to wake up to a 5% gap down because sentiment shifted overnight.
Healthcare ETFs Positioned to Benefit
If this rotation continues, healthcare ETFs are the obvious beneficiaries. Here are three worth watching:
Health Care Select Sector SPDR Fund (XLV): This is the large-cap healthcare benchmark, tracking the Health Care Select Sector Index with heavyweight allocations to Lilly, UNH, and J&J. For investors looking for liquidity and broad exposure that mirrors hedge fund positioning, XLV remains the go-to choice.
VanEck Pharmaceutical ETF (PPH): This fund takes a tighter, pharma-focused approach with high weights in Lilly, Novo Nordisk (NVO), and Merck & Co Inc (MRK). If hedge funds keep doubling down on blockbuster drug stories—particularly obesity and oncology—PPH is positioned to capture that momentum.
Vanguard Health Care ETF (VHT): For investors who want diversification, VHT mixes big pharma, biotech, and healthcare services. The broader exposure makes it suitable for anyone seeking defensive stability alongside exposure to innovation cycles across the sector.
Why This Matters Now
If hedge funds continue recalibrating away from ultra-concentrated tech bets, healthcare ETFs may be among the more reliable beneficiaries of Q4 positioning shifts. The sector offers a rare combination: downside protection, earnings visibility, and secular drug-pipeline tailwinds. That's a mix that's proving hard for smart money to ignore.
It's not that tech is dead or that healthcare is suddenly exciting. It's simpler than that. After a year of riding tech momentum, managers are looking at their portfolios and realizing they could use some stocks that actually make money whether or not the next earnings call mentions AI seventeen times. Healthcare fits that bill perfectly.